What were the main drivers of revenue growth in the third quarter and year-to-date?

Revenue growth was primarily driven by the Companion Animal Group (CAG), which saw significant increases from sales of the new LaserCyte® system, along with higher sales of instrument consumables, laboratory services, and rapid assay products. The Food and Environmental Group (FEG) also contributed to growth, mainly through increased water testing product sales, partly supported by favorable currency exchange rates.

How is the company's profitability trending?

Profitability is trending positively, with net income increasing to $44.7 million for the nine months ended September 30, 2003, up from $32.6 million in the prior year. Gross profit margin improved slightly to 48% from 47% for the same period, and operating income saw a substantial increase of 38%.

What is the company's financial position in terms of liquidity and cash flow?

The company maintains a strong financial position. Cash and cash equivalents increased significantly to $176.9 million as of September 30, 2003. Cash flow from operations remained robust, providing $91.8 million for the nine months ended September 30, 2003. The company believes it has sufficient resources to fund its operations and capital requirements.

Are there any significant new agreements or developments impacting future operations?

Yes, IDEXX entered into a new supply agreement with Ortho-Clinical Diagnostics, Inc. for VetTest® chemistry analyzer consumables through 2018. This agreement includes the development of a next-generation chemistry analyzer. The company also expects a non-cash charge of approximately $7.3 million in the fourth quarter of 2003 related to discontinuing certain internal development activities for an alternative instrument.

IDXX 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong financial results for the nine months ended September 30, 2003. Total revenue increased by 14% to $351.2 million, driven by robust growth in the Companion Animal Group (CAG), which saw an 17% revenue increase. The Food and Environmental Group (FEG) also contributed with a 6% revenue increase. Net income for the period rose significantly to $44.7 million, up from $32.6 million in the prior year, reflecting improved operational efficiency and strategic growth initiatives. Key financial highlights include a substantial increase in operating income, with the CAG segment showing a 43% year-over-year growth. The company's balance sheet remains strong, with total assets growing to $497.2 million, supported by significant increases in cash and cash equivalents. IDEXX has also continued its share repurchase program and entered into a new supply agreement for its VetTest® chemistry analyzer consumables, extending its relationship with Ortho-Clinical Diagnostics, Inc. The company appears well-positioned for continued growth, with a focus on product innovation and market expansion.

Key Highlights

1Total revenue increased 14% to $351.2 million for the nine months ended September 30, 2003, compared to $306.8 million in the prior year.
2Net income for the nine-month period rose to $44.7 million, a significant increase from $32.6 million in the same period of 2002.
3Companion Animal Group (CAG) revenue grew 17% to $284.0 million, driven by strong performance in instruments, consumables, and laboratory services.
4Operating income increased by 38% to $65.1 million for the nine-month period, indicating improved profitability.
5Cash and cash equivalents grew substantially, reaching $176.9 million at September 30, 2003, up from $113.8 million at December 31, 2002.
6The company entered into a new long-term supply agreement for VetTest® chemistry analyzer consumables through 2018.
7Share repurchase program remains active, with authorization for an additional 2 million shares in October 2003.

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions